CEL-SCI Corp
cel-sci.comWhat Do They Do?
Develops immune-based treatment candidates for cancer and other diseases, including Multikine for certain head and neck cancers and LEAPS-based candidates for rheumatoid arthritis.
10-K for FY2025, filed Dec 29, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Aug 14, 2026
−$5.7MView ↗
- ▲ 0% (Loss)
- vs −$5.7M in Q3 FY2025
-
May 14, 2026
Signs Saudi Arabia commercialization and distribution agreement
Amarox will handle local regulatory work and, if approved, distribute Multikine exclusively in Saudi Arabia; the companies will share net sales revenue.
Sources
8-K, filed May 14, 2026
On May 11,2026 , the Company issued a press release, filed as Exhibit 99, concerning a strategic partnership, distribution, and revenue…View ↗
Who Do They Compete With?
Competes with Merck
10-K for FY2025, filed Dec 29, 2025Keytruda was approved by FDA in June 2025 as a perioperative (before and after surgery) treatment for resectable locally advanced head and…View ↗
Loading...
